[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients
First Affiliated Hospital of Chongqing Medical University
30 participants
May 30, 2024
INTERVENTIONAL
Conditions
Summary
Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING therapy. This study will investigate the safety, biodistribution and potential usefulness of a novel 68Ga-labeled agonist (\[68Ga\]Ga-Sa-DABI-4) for noninvasive positron emission tomography (PET) imaging of STING expression in the tumor microenvironment.
Eligibility
Inclusion Criteria3
- At least 18 years of age.
- Signed informed consent.
- Patients with suspected or newly diagnosed or previously malignant disease.
Exclusion Criteria5
- Patients with non-malignant disease.
- Patients with pregnancy.
- The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
- Known or expected hypersensitivity to \[68Ga\]Ga-Sa-DABI-4 or any of its components.
- Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06419361